Please assess the completion status of the following clinical trial:

Trial Title: Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 to 70 years~* Non-diabetic~* Unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter~* Serum creatinine level within normal range~* Ability to tolerate oral fluids and oral pain medication~* Ability to make informed medical decisions regarding consent~* Willingness to follow up in the ER in two weeks~Exclusion Criteria:~* Adults unable to consent~* Age \<18~* Signs of infection including Temperature \>38º C or Urinalysis with any of the following: Positive Leukocyte Esterase, Positive Nitrates, or White Blood Cell Count \>5/hfp in the setting of a positive urine culture (defined as a single isolated bacterial species population of \>100,000 CFU)~* Patients with chronic pain already undergoing treatment with narcotic medications~* Patients already taking an alpha adrenergic antagonist medication~* Pregnant women~* Prisoners~* No working phone number

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Silodosin (Type: ACTIVE_COMPARATOR): Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
- Tamsulosin (Type: ACTIVE_COMPARATOR): Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).